The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis

The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis

Abstract Background The role of adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) is not clear in early‐stage nonsmall‐cell lung cancer (NSCLC) patients. This meta‐analysis aims to compare the efficacy and safety of EGFR‐TKIs as adjuvant therapy with chemotherapy or pl...

Full description

Bibliographic Details
Main Authors: Chutong Lin, Fengling Hu, Hongling Chu, Peng Ren, Shanwu Ma, Jingdi Wang, Jie Bai, Xuan Han, Shaohua Ma
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Thoracic Cancer
Subjects:
adjuvant treatment
epidermal growth factor receptor tyrosine kinase inhibitors
nonsmall‐cell lung cancer
survival
targeted therapy
Online Access:https://doi.org/10.1111/1759-7714.13874

Internet

https://doi.org/10.1111/1759-7714.13874

Similar Items